✦ LIBER ✦

Alvimopan: An oral, peripherally acting, μ-opioid receptor antagonist for the treatment of opioid-induced bowel dysfunction—A 21-day treatment-randomized clinical trial

✍ Scribed by Daniel M. Paulson; Daniel T. Kennedy; Roger A. Donovick; Randall L. Carpenter; Maryann Cherubini; Lee Techner; Wei Du; Yuju Ma; William K. Schmidt; Bruce Wallin; David Jackson

Book ID: 119306348
Publisher: Elsevier Science
Year: 2005
Tongue: English
Weight: 696 KB
Volume: 6
Category: Article
ISSN: 1528-8447
DOI: 10.1016/j.jpain.2004.12.001

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Novel therapeutic agents: Alvimopan, a n

Novel therapeutic agents: Alvimopan, a novel, peripherally-acting, mu-opioid receptor antagonist for the management of opioid-induced bowel dysfunction (OBD): Positive results from a phase III randomized, placebo-controlled, 21-day trial

✍ D. Paulson; D. Kennedy; R. Donovick; R. Carpenter; M. Cherubini; L. Techner; W. 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 54 KB

Alvimopan, a peripherally acting mu-opio

Alvimopan, a peripherally acting mu-opioid receptor (PAM-OR) antagonist for the treatment of opioid-induced bowel dysfunction: Results from a randomized, double-blind, placebo-controlled, dose-finding study in subjects taking opioids for chronic non-cancer pain

✍ Lynn Webster; Jan Peter Jansen; John Peppin; Ben Lasko; Gordon Irving; Bart Morl 📂 Article 📅 2008 🏛 Elsevier Science 🌐 English ⚖ 723 KB